Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Receivables (2021 - 2025)

Historic Receivables for Regenerative Medical Technology (RMTG) over the last 5 years, with Q3 2025 value amounting to $8.3 million.

  • Regenerative Medical Technology's Receivables rose 100.84% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 100.84%. This contributed to the annual value of $8.2 million for FY2024, which is 1.64% down from last year.
  • As of Q3 2025, Regenerative Medical Technology's Receivables stood at $8.3 million, which was up 100.84% from $8.2 million recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's Receivables ranged from a high of $8.3 million in Q3 2025 and a low of $34513.0 during Q4 2021
  • Moreover, its 5-year median value for Receivables was $8.2 million (2022), whereas its average is $5.4 million.
  • In the last 5 years, Regenerative Medical Technology's Receivables skyrocketed by 2380335.82% in 2022 and then crashed by 9937.66% in 2023.
  • Quarter analysis of 5 years shows Regenerative Medical Technology's Receivables stood at $34513.0 in 2021, then skyrocketed by 23803.36% to $8.2 million in 2022, then dropped by 0.31% to $8.2 million in 2023, then fell by 0.02% to $8.2 million in 2024, then grew by 1.11% to $8.3 million in 2025.
  • Its Receivables stands at $8.3 million for Q3 2025, versus $8.2 million for Q2 2025 and $8.2 million for Q1 2025.